Notch Signaling, Hypoxia, and Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Feb 17

PMID 36798826

Authors

Mingzhou Guo

Yang Niu

Min Xie

Xiansheng Liu

Xiaochen Li

Affiliations

Soon will be listed here.

Abstract

Notch signaling is involved in cell fate determination and deregulated in human solid tumors. Hypoxia is an important feature in many solid tumors, which activates hypoxia-induced factors (HIFs) and their downstream targets to promote tumorigenesis and cancer development. Recently, HIFs have been shown to trigger the Notch signaling pathway in a variety of organisms and tissues. In this review, we focus on the pro- and anti-tumorigenic functions of Notch signaling and discuss the crosstalk between Notch signaling and cellular hypoxic response in cancer pathogenesis, including epithelia-mesenchymal transition, angiogenesis, and the maintenance of cancer stem cells. The pharmacological strategies targeting Notch signaling and hypoxia in cancer are also discussed in this review.

Citing Articles

Epigenetic activation of JAG1 by AID contributes to metastasis of hepatocellular carcinoma.

Jiao J, Shao K, Liu Z, Liu L, Nie Z, Wu J J Biol Chem. 2024; 301(1):108078.

PMID: 39675704 PMC: 11758938. DOI: 10.1016/j.jbc.2024.108078.

Exploring the role of antigen-presenting cancer-associated fibroblasts and CD74 on the pancreatic ductal adenocarcinoma tumor microenvironment.

Thomas M, Jie E, Kim A, Mayberry T, Cowan B, Luechtefeld H Med Oncol. 2024; 42(1):15.

PMID: 39585543 DOI: 10.1007/s12032-024-02564-6.

Hypoxia-induced DTL promotes the proliferation, metastasis, and sorafenib resistance of hepatocellular carcinoma through ubiquitin-mediated degradation of SLTM and subsequent Notch pathway activation.

Chen Z, Mu M, Yang G, Qi H, Fu X, Wang G Cell Death Dis. 2024; 15(10):734.

PMID: 39384740 PMC: 11464529. DOI: 10.1038/s41419-024-07089-4.

[ORY-1001 inhibits glioblastoma cell growth by downregulating the Notch/HES1 pathway suppressing lysine-specific demethylase 1 expression].

Yang H, Xiang Y, Tan T, Lei Y Nan Fang Yi Ke Da Xue Xue Bao. 2024; 44(8):1620-1630.

PMID: 39276059 PMC: 11378054. DOI: 10.12122/j.issn.1673-4254.2024.08.22.

Factors Determining Epithelial-Mesenchymal Transition in Cancer Progression.

Tomecka P, Kunachowicz D, Gorczynska J, Gebuza M, Kuznicki J, Skinderowicz K Int J Mol Sci. 2024; 25(16).

PMID: 39201656 PMC: 11354349. DOI: 10.3390/ijms25168972.

References

Zweidler-McKay P, He Y, Xu L, Rodriguez C, Karnell F, Carpenter A . Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies. Blood. 2005; 106(12):3898-906. PMC: 1895093. DOI: 10.1182/blood-2005-01-0355. View

Vaupel P, Mayer A . Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007; 26(2):225-39. DOI: 10.1007/s10555-007-9055-1. View

Bai L, Wang A, Zhang Y, Xu X, Zhang X . Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway. Exp Cell Res. 2018; 366(2):161-171. DOI: 10.1016/j.yexcr.2018.03.014. View

Zeng Q, Li S, Chepeha D, Giordano T, Li J, Zhang H . Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell. 2005; 8(1):13-23. DOI: 10.1016/j.ccr.2005.06.004. View

Danson S, Johnson P, Ward T, Dawson M, Denneny O, Dickinson G . Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1. Ann Oncol. 2011; 22(7):1653-1660. DOI: 10.1093/annonc/mdq638. View

Astudillo L, Da Silva T, Wang Z, Han X, Jin K, VanWye J . The Small Molecule IMR-1 Inhibits the Notch Transcriptional Activation Complex to Suppress Tumorigenesis. Cancer Res. 2016; 76(12):3593-603. PMC: 4911243. DOI: 10.1158/0008-5472.CAN-16-0061. View

Wu D, Wang S, Oliveira D, Del Gaudio F, Vanlandewijck M, Lebouvier T . The infantile myofibromatosis NOTCH3 L1519P mutation leads to hyperactivated ligand-independent Notch signaling and increased PDGFRB expression. Dis Model Mech. 2021; . PMC: 7927659. DOI: 10.1242/dmm.046300. View

Ravaud A, Bernhard J, Gross-Goupil M, Digue L, Ferriere J . [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma]. Bull Cancer. 2010; 97:45-51. DOI: 10.1684/bdc.2010.1069. View

Sun Y, Lowther W, Kato K, Bianco C, Kenney N, Strizzi L . Notch4 intracellular domain binding to Smad3 and inhibition of the TGF-beta signaling. Oncogene. 2005; 24(34):5365-74. DOI: 10.1038/sj.onc.1208528. View

10.

Main H, Lee K, Yang H, Haapa-Paananen S, Edgren H, Jin S . Interactions between Notch- and hypoxia-induced transcriptomes in embryonic stem cells. Exp Cell Res. 2009; 316(9):1610-24. DOI: 10.1016/j.yexcr.2009.12.012. View

11.

Taylor S, Metch B, Balcerzak S, HANSON K . Phase II trial of echinomycin in advanced soft tissue sarcomas. A Southwest Oncology Group study. Invest New Drugs. 1990; 8(4):381-3. DOI: 10.1007/BF00198595. View

12.

Tinley T, Leal R, Randall-Hlubek D, Cessac J, Wilkens L, Rao P . Novel 2-methoxyestradiol analogues with antitumor activity. Cancer Res. 2003; 63(7):1538-49. View

13.

Price C, Gill S, Ho Z, Davidson S, Merkel E, McFarland J . Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers. Cancer Res. 2019; 79(10):2564-2579. PMC: 6522283. DOI: 10.1158/0008-5472.CAN-18-2674. View

14.

Ho A, Ochoa A, Jayakumaran G, Zehir A, Valero Mayor C, Tepe J . Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. J Clin Invest. 2019; 129(10):4276-4289. PMC: 6763222. DOI: 10.1172/JCI128227. View

15.

Zheng X, Linke S, Dias J, Zheng X, Gradin K, Wallis T . Interaction with factor inhibiting HIF-1 defines an additional mode of cross-coupling between the Notch and hypoxia signaling pathways. Proc Natl Acad Sci U S A. 2008; 105(9):3368-73. PMC: 2265116. DOI: 10.1073/pnas.0711591105. View

16.

Rodriguez C, Wu Q, Voutsinas J, Fromm J, Jiang X, Pillarisetty V . A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer. Clin Cancer Res. 2019; 26(4):837-845. DOI: 10.1158/1078-0432.CCR-19-2214. View

17.

Irshad K, Mohapatra S, Srivastava C, Garg H, Mishra S, Dikshit B . A combined gene signature of hypoxia and notch pathway in human glioblastoma and its prognostic relevance. PLoS One. 2015; 10(3):e0118201. PMC: 4348203. DOI: 10.1371/journal.pone.0118201. View

18.

Wu D, Potluri N, Lu J, Kim Y, Rastinejad F . Structural integration in hypoxia-inducible factors. Nature. 2015; 524(7565):303-8. DOI: 10.1038/nature14883. View

19.

Li X, Cao X, Zhao H, Guo M, Fang X, Li K . Hypoxia Activates Notch4 via ERK/JNK/P38 MAPK Signaling Pathways to Promote Lung Adenocarcinoma Progression and Metastasis. Front Cell Dev Biol. 2022; 9:780121. PMC: 8721100. DOI: 10.3389/fcell.2021.780121. View

20.

Krishnamachary B, Zagzag D, Nagasawa H, Rainey K, Okuyama H, Baek J . Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res. 2006; 66(5):2725-31. DOI: 10.1158/0008-5472.CAN-05-3719. View